Galectin Therapeutics reported $-12.37M in Net Income for its fiscal quarter ending in June of 2024.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Galectin Therapeutics USD -12.37M 880K Jun/2024
Gilead Sciences USD -10.5B 12.52B Jun/2026
Immunic USD -19.3M 6.28M Dec/2025
Incyte USD 585.6M 282.27M Jun/2026
Merck USD -1.34B 2.9B Jun/2026